+1-888-308-5802     
News Contact Us

Hikma and Arecor ink new deal to develop and market new medicines

Author : Saipriya Iyer | Published Date : 2020-01-11 

Hikma Pharmaceuticals, a renowned UK based biopharmaceutical company, and Arecor, a biopharmaceutical firm advancing today’s treatments to enable healthier lives, have reportedly signed a new strategic agreement to develop a novel injectable medicine in the U.S. from Hikma’s subsidiary, Hikma Pharmaceuticals USA Inc.

The new product, which would be unveiled before launch, is being developed utilizing Arestat™, a proprietary drug formulation technology platform of Arecor. Arestat improves the characteristics of authorized therapeutic peptides and proteins to provide new reformulations of complex, existing products.

Hikma would seek authorization for this product under the U.S. FDA’s (Food and Drug Administration) 505(b)(2) regulatory pathway. The filing is expected to take place in 2021.

President of Hikma Injectables, Riad Mishlawi stated that the company is thrilled to enter this collaboration with Arecor. This is one more vital step ahead for Hikma in developing and marketing complex medicines as well as delivery systems that help patients and position the company’s business for seamless long-term growth.  

Mishlawi further added that the company is confident that this innovative development platform of Arecor, together with Hikma’s robust production capabilities and outstanding commercial team, with its strong connections across US hospital systems, would bring a vital new therapy option to healthcare providers and patients.

Chief Executive Officer of Arecor, Sarah Howell stated that the company is proud to be operating with Hikma. The company has an outstanding track record in developing RTU (ready-to-use) and RTA (ready-to-administer) medicines. These medicines have become increasingly important in order to enable safe, fast and effective therapy of patients. 

Howell further added that Hikma has a respected and robust US hospital industry presence. The company is also focused at providing cost-effective treatments that advance the delivery of medication and enhance patient care. The company now looks forward to the combined development of this initial product as a part of the wide collaboration with Hikma.

 

Source credit: https://www.hikma.com/newsroom/article-i4639-hikma-and-arecor-announce-exclusive-agreement-to-develop-and-commercialise-ready-to-use-medicine-using-arestat-technology/

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Broco Tactical to unveil 3 new products at 2020 SHOT Show in Las Vegas

Published Date: 2020-01-21         Author: Saipriya Iyer

Broco Tactical is reportedly introducing the latest line of forced entry and rescue & repair products in Las Vegas, Nevada, for military, law enforcement, and first responders at 2020 SHOT Show, from 21st-24th January. The California-based company is a part of the Broco Rankin family of companie... Read More

Zymeworks partners with Ibrance and initiates Phase 2 trial

Published Date: 2020-01-14         Author: Saipriya Iyer

Zymeworks Inc., a Vancouver based clinical stage biopharmaceutical company that develops multifunctional therapeutics, has reportedly announced the commencement of Phase 2 trial that assesses ZW25 combination therapy. The company also announced that it has reached consensus on an agreement with Pfiz... Read More

Takata recalls 10mil air bag inflators as part of 2015 U.S. settlement

Published Date: 2020-01-09         Author: Saipriya Iyer

Japanese automotive parts manufacturing firm Takata Corporation has reportedly recalled close to 10 million front air bag inflators that were sold to 14 different automotive makers. These products pose a risk of exploding with extreme force and throw shrapnel. For the record, the 10 million infla... Read More

© 2020 Fractovia. All Rights Reserved